KPMG's latest report on China's life science sector notes that the country is set to become a crucial player in the life science and healthcare industry. Within a decade it is expected to become a global leader in drug discovery and innovation.
This report makes a compelling read for any organisation that is either planning or implementing a cloud strategy, and provides some practical and actionable advice for enterprises and their executives.
Please contact us if you have any questions about our services or on any other matter. You are also welcome to contact Partners and staff of the Valuation & Modelling service team.
Head of Valuation Services, China and HK SAR
+852 2140 2818
+86 (10) 8508 5810
+86 (21) 2212 3660
Subscribe to receive email alerts or e-Newsletters from KPMG China when new updates are available.
KPMG Advisory (China) Limited, a wholly foreign owned enterprise in China and KPMG Huazhen (Special General Partnership), a special general partnership in China, are member firms of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved.
© 2013 KPMG, a Hong Kong partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved.
The KPMG name, logo and “cutting through complexity” are registered trademarks or trademarks of KPMG International.
KPMG International Cooperative (“KPMG International”) is a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.